Topline results anticipated in Q4 2024 for Phase 2 trial evaluating the safety and tolerability of OCS-05 in patients with Acute Optic Neuritis (AON) ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- ...
"This is an important milestone that underscores Penumbra's commitment to transforming care for patients with pulmonary embolism," said James F. Benenati, MD, FSIR, chief medical officer at Penumbra. ...
SAN JOSE, Calif.--(BUSINESS WIRE)--Shape Memory Medical Inc., developer of custom shape memory polymers for endovascular markets, announced the first enrollment in Europe in the AAA-SHAPE Pivotal ...
Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback